Phase 2b trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intra-articular injection in knee osteoarthritis
Arthritis & Rheumatism Nov 05, 2017
Conaghan PG, et al. - The analgesic benefits of two FX006 doses with saline-placebo injection was compared in this study. Although the primary endpoint was not met, FX006 exhibited a prolonged reduction in symptoms with an evident dose response and a safety profile similar to that of saline-placebo.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
